Testosterone for low libido in postmenopausal women not taking estrogen.

@article{Davis2008TestosteroneFL,
  title={Testosterone for low libido in postmenopausal women not taking estrogen.},
  author={Susan R. Davis and Mich{\`e}le Moreau and Robin Kroll and C{\'e}line Bouchard and Nick Panay and Margery L. S. Gass and Glenn D Braunstein and Angelica Lind{\'e}n Hirschberg and Cynthia A. Rodenberg and Simon Pack and Helga Koch and Alain Moufarege and John W. W. Studd},
  journal={The New England journal of medicine},
  year={2008},
  volume={359 19},
  pages={
          2005-17
        }
}
  • S. DavisM. Moreau J. Studd
  • Published 6 November 2008
  • Medicine, Psychology, Biology
  • The New England journal of medicine
BACKGROUND The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. METHODS We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a… 

Figures and Tables from this paper

Testosterone treatment of HSDD in naturally menopausal women: the ADORE study

TTP was effective in treating HSDD and improving sexual function in this study of naturally menopausal women with and without concurrent hormone therapy.

Testosterone for low libido in postmenopausal women?

  • M. RothJ. Amory
  • Medicine, Biology
    Expert review of endocrinology & metabolism
  • 2009
The results of this trial confirm the improvement in sexual function for postmenopausal women seen in earlier studies using testosterone in combination with estradiol, implying thatEstradiol administration may not be essential for the beneficial effects of testosterone.

Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.

Randomized, double-blind, placebo-controlled studies have established the efficacy of the transdermal testosterone patch for relieving symptoms of HSDD in surgically and naturally menopausal women with and without concomitant estrogen or estrogen/progestin therapy.

The role of testosterone in menopausal hormone treatment. What is the evidence?

Treatment with transdermal (patch) testosterone improved sexual function in several randomized controlled trials and women with hypoactive sexual desire disorder who were treated with testosterone reported more satisfying sexual episodes and sexual desire.

Review: Testosterone therapy for reduced libido in women

  • R. Basson
  • Medicine, Psychology
    Therapeutic advances in endocrinology and metabolism
  • 2010
An increased frequency of satisfying sexual encounters and intensity of sexual desire and response has been shown in medically and psychiatrically healthy women able to have 2—3 satisfying sexual experiences each month before therapy commences.

Safety of testosterone use in women.

Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial.

TT therapy resulted in a significant increase in the number of SSEs compared with Pl therapy in women with SSRI/SNRI-emergent loss of libido who need to remain on their antidepressant therapy, providing the first evidence that TT therapy may be a treatment option.

Safety of testosterone therapy indicated for hypoactive sexual desire disorder in postmenopausal women

Overall, there is still a lack of clarity on the safety of using testosterone therapy for HSDD in postmenopausal women and data from further studies are needed to draw a firm conclusion.

The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review

It is concluded that testosterone is a vital hormone in women in maintaining sexual health and function and Testosterone Replacement Therapy (TRT) is an effective treatment option for postmenopausal people with HSDD.
...

References

SHOWING 1-10 OF 68 REFERENCES

Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study

Testosterone patch treatment increased the frequency of satisfying sexual activity and sexual desire, decreased personal distress, and was well tolerated in naturally menopausal women with hypoactive sexual desire disorder.

Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial

Transdermal testosterone therapy via a skin patch improved sexual desire and other sexual function domains and was well tolerated in these oophorectomized women with HSDD receiving concomitant transdermal estrogen.

Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.

In the Intimate SM 1 study, the testosterone patch improved sexual function and decreased distress in surgically menopausal women with HSDD and was well tolerated in this trial.

Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women

The findings suggest that testosterone therapy may benefit women presenting with low libido in their late reproductive years, and several doses of testosterone, administered transdermally by a metered-dose spray system, in increasing self-reported sexual satisfaction among premenopausal women who had decreased sexual satisfaction.

Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.

Surgically menopausal women with HSDD in these studies received clinically meaningful benefits, including improvements in satisfying sexual activity, sexual desire, and personal distress.

The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials

Double-blind randomized controlled trials of estrogen and/or testosterone on sexual function among natural or surgical menopause in women are reviewed and whether specific serum hormone levels are related to sexual functioning and how these group effects apply to individual women are unclear.

Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women

Addition of testosterone may counteract breast cell proliferation as induced by estrogen/progestogen therapy in postmenopausal women.
...